In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
27 authors.
Xiao Lei ChenUniversity of California San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, La Jolla, CA.ORCID 0000-0001-7998-9963 Kevin M TharpSanford Burnham Prebys Discovery Institute, Cancer Metabolism and Microenvironment Program, La Jolla, CA.ORCID 0000-0002-3543-3266 Marjaana OjalillUniversity of California San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, La Jolla, CA.ORCID 0000-0003-3181-6742 Duygu OzmadenciUniversity of California San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, La Jolla, CA.ORCID 0000-0002-5463-7766 Antonia BoyerUniversity of California San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, La Jolla, CA.ORCID 0009-0008-2716-8280 Terrance J Hannen IiiUniversity of California San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, La Jolla, CA.ORCID 0000-0003-1461-3169 Christine LawsonUniversity of California San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, La Jolla, CA.ORCID 0009-0006-5682-0851 Hyojae James LeeUniversity of California San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, La Jolla, CA.ORCID 0000-0003-3079-5484 Marvin XiaUniversity of California San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, La Jolla, CA.ORCID 0009-0008-2712-0922 Elise TahonUniversity of California San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, La Jolla, CA.ORCID 0009-0002-0136-6162 Yichi ZhangUniversity of California San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, La Jolla, CA.ORCID 0009-0009-8032-7487 Cray MinorSanford Burnham Prebys Discovery Institute, Cancer Metabolism and Microenvironment Program, La Jolla, CA.
Safir Ullah KhanUniversity of California San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, La Jolla, CA.
Colin C AndersonDepartment of Biochemistry and Molecular Genetics, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0001-7815-2416 Travis NemkovDepartment of Biochemistry and Molecular Genetics, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0001-8566-7119 Michael RoseUniversity of California San Diego, Department of Pathology, Moores Cancer Center, La Jolla, CA.
Monica V EstradaUniversity of California San Diego, Department of Pathology, Moores Cancer Center, La Jolla, CA.ORCID 0000-0001-9846-8223 Alfredo A MolinoloUniversity of California San Diego, Department of Pathology, Moores Cancer Center, La Jolla, CA.ORCID 0000-0001-8412-2889 Elias WarrenUniversity of California San Diego, Department of Pathology, Moores Cancer Center, La Jolla, CA.
Patrick PenolosaUniversity of California San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, La Jolla, CA.
Ramez N EskanderUniversity of California San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, La Jolla, CA.ORCID 0000-0002-2101-1935 Michael T McHaleUniversity of California San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, La Jolla, CA.
Shizhen E WangUniversity of California San Diego, Department of Pathology, Moores Cancer Center, La Jolla, CA.ORCID 0000-0002-5036-8175 Denise C ConnollyFox Chase Cancer Center, Cancer Signaling and Microenvironment Program, Philadelphia, PA.ORCID 0000-0003-0888-2004 Kathleen M FischUniversity of California San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Maternal and Fetal Medicine, La Jolla, CA.ORCID 0000-0002-0117-7444 Dwayne G StupackUniversity of California San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, La Jolla, CA.ORCID 0000-0003-4396-5745 David D SchlaepferUniversity of California San Diego, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, Division of Gynecologic Oncology, La Jolla, CA.ORCID 0000-0003-4814-9210 Funding
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9MUC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3MUCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3MDissecting FAK-regulated oncogenic signaling programs in ovarian cancerR01CA247562 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SCHLAEPFER, DAVID D, STUPACK, DWAYNE G. · 2020 to 2024
$2.3MReprogramming the Tumor Microenvironment in Ovarian CancerR01CA254342 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SCHLAEPFER, DAVID D · 2020 to 2024
$2.1MIllumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600kNCATS NIH HHS UL1 TR001442NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA247562NCI NIH HHS R01 CA254342NCI NIH HHS T32 CA121938NIH HHS S10 OD026929
6 · The paper itselfAbstract
High grade serous ovarian cancer (HGSOC) is the most lethal gynecologic malignancy in the USA due to chemo- and immuno-therapy resistance. We show that focal adhesion kinase (FAK) inhibition with ifebemtinib or tumor genetic FAK knockout (KO) in syngeneic ovarian tumor models stimulated resident large peritoneal macrophages to express CXCL13 chemokine and promoted B cell infiltration. Macrophage GATA6 inactivation prevented CXCL13 expression and enhanced FAK-KO tumor growth. Combining ifebemtinib with pegylated doxorubicin chemotherapy and anti-TIGIT immune checkpoint antibody extended survival with tumor-associated tertiary lymphoid structure formation. Mechanistically, FAK-KO heat-treated conditioned media contained exosomes enriched with omega-3 fatty acids which stimulated macrophage CXCL13 production. Ifebemtinib-treated tumors, FAK-KO exosomes, and purified eicosapentaenoic acid enhanced murine and human HGSOC-associated tumor macrophage reprogramming and CXCL13 expression. Overall, our studies define a tumor to macrophage signaling linkage via omega-3 exosome lipids supporting B cell recruitment, survival, immunotherapy enhancement, and actionable via small molecule FAK inhibition.
Identifiers
PMID41000740
PMCPMC12458239
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390